Treatment with butyrate alleviates dextran sulfate sodium and Clostridium difficile-induced colitis by preventing activity of Th17 cells via regulation of SIRT1/mTOR in mice

Wang, Siqi; Deng, Wen; Li, Fang; Xiang, Leyang; Lv, Pinjing; Chen, Ye

doi:10.1016/j.jnutbio.2022.109155

Cited by 19 publications

(16 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C57BL/6 J mice did not manifest diarrhea, and furthermore, the pathological changes in their intestine were not significant. This finding is inconsistent with the previously reported findings ( Chen et al, 2008 ; Wang et al, 2022 ). Histopathology in Mongolian gerbil is a typical histologic feature of CDI.…”

Section: Discussioncontrasting

confidence: 99%

Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge

Wan,

You,

Shi

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionClostridioides difficile infection (CDI), as well as its etiology and pathogenesis, have been extensively investigated. However, the absence of suitable CDI animal models that reflect CDI symptoms and the associated gut microbiome changes in humans has limited research progress in this field. Thus, we aimed to investigate whether Mongolian gerbils, which present a range of human pathological conditions, can been used in studies on CDI. Methods: In this study, we infected Mongolian gerbils and two existing CDI model animals, mice and hamsters, with the hypervirulent ribotype 027 C. difficile strain, and comparatively analyzed changes in their gut microbiome composition via 16S rRNA gene sequencing.MethodsIn this study, we infected Mongolian gerbils and two existing CDI model animals, mice and hamsters, with the hypervirulent ribotype 027 C. difficile strain, and comparatively analyzed changes in their gut microbiome composition via 16S rRNA gene sequencing.ResultsThe results obtained showed that C. difficile colonized the gastrointestinal tracts of the three rodents, and after the C. difficile challenge, C57BL/6J mice did not manifest CDI symptoms and their intestines showed no significant pathological changes. However, the hamsters showed explosive intestinal bleeding and inflammation and the Mongolian gerbils presented diarrhea as well as increased infiltration of inflammatory cells, mucus secretion, and epithelial cell shedding in their intestinal tissue. Further, intestinal microbiome analysis revealed significant differences with respect to intestinal flora abundance and diversity. Specifically, after C. difficile challenge, the Firmicutes/Bacteroidetes ratio decreased for C57BL/6J mice, but increased significantly for Mongolian gerbils and hamsters. Furthermore, the abundance of Proteobacteria increased in all three models, especially in hamsters, while that of Verrucomicrobia only increased significantly in C57BL/6J mice and Mongolian gerbils. Our results also indicated that differences in the relative abundances of Lactobacillaceae and Akkermansia were primarily responsible for the observed differences in response to C. difficile challenge.ConclusionBased on the observed responses to C. difficile challenge, we concluded for the first time that the Mongolian gerbil could be used as an animal model for CDI. Additionally, the taxa identified in this study may be used as biomarkers for further studies on CDI and to improve understanding regarding changes in gut microbiome in CDI-related diseases.

show abstract

Section: Discussioncontrasting

confidence: 99%

Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge

Wan,

You,

Shi

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Research demonstrating the inhibition of SIRT1 by butyric acid suggests that SCFAs can indirectly inhibit HDAC Class III by influencing the NAD+/NADH ratio. [74] Experimental evidence indicates that by, leveraging the inhibitory effects of HDACs in 1-methyl-4-phenylpyridinium (MPP)/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)induced PD models, β-hydroxybutyric acid disrupts the STAT3/ NLRP3/GSDMD signaling pathway, effectively alleviating clinical and pathological symptoms of PD. [75] Furthermore, post-HDAC inhibition, SCFAs enhance the expression of neurotrophic factors, glial cell-derived neurotrophic factor and brain-derived neurotrophic factor (BDNF) on astrocytes, thereby exerting a protective effect on dopamine neurons.…”

Section: Scfas Suppress Histone Deacetylationmentioning

confidence: 99%

Interplay of human gastrointestinal microbiota metabolites: Short-chain fatty acids and their correlation with Parkinson’s disease

Liu,

Chen,

2024

Medicine

View full text Add to dashboard Cite

Short-chain fatty acids (SCFAs) are, the metabolic byproducts of intestinal microbiota that, are generated through anaerobic fermentation of undigested dietary fibers. SCFAs play a pivotal role in numerous physiological functions within the human body, including maintaining intestinal mucosal health, modulating immune functions, and regulating energy metabolism. In recent years, extensive research evidence has indicated that SCFAs are significantly involved in the onset and progression of Parkinson disease (PD). However, the precise mechanisms remain elusive. This review comprehensively summarizes the progress in understanding how SCFAs impact PD pathogenesis and the underlying mechanisms. Primarily, we delve into the synthesis, metabolism, and signal transduction of SCFAs within the human body. Subsequently, an analysis of SCFA levels in patients with PD is presented. Furthermore, we expound upon the mechanisms through which SCFAs induce inflammatory responses, oxidative stress, abnormal aggregation of alpha-synuclein, and the intricacies of the gut-brain axis. Finally, we provide a critical analysis and explore the potential therapeutic role of SCFAs as promising targets for treating PD.

show abstract

“…SCFAs such as butyrate have a protective effect against IBD by regulating Th17/Treg balance. 36 Deoxycholic acid aggravates intestinal inflammation via promoting the expression of IL-1β and the proportion of CD3 + and CD4 + T cells and reducing the number of tuft cells. 37 A consortium of Clostridium AP sp000509125, Bacteroides ovatus and Eubacterium limosum could produce secondary bile acids ursodeoxycholic acid and lithocholic acid to improve gut-barrier integrity in colitis mice.…”

Section: Disease Pathogenesismentioning

confidence: 99%

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Bai,

Wang,

et al. 2024

Science Progress

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.

show abstract

Treatment with butyrate alleviates dextran sulfate sodium and Clostridium difficile-induced colitis by preventing activity of Th17 cells via regulation of SIRT1/mTOR in mice

Cited by 19 publications

References 61 publications

Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge

Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge

Interplay of human gastrointestinal microbiota metabolites: Short-chain fatty acids and their correlation with Parkinson’s disease

Research advancements and perspectives of inflammatory bowel disease: A comprehensive review

Contact Info

Product

Resources

About